Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective was to determine the safety, tolerability and maximum tolerate dose
(MTD) of BIBF 1120 in combination with pemetrexed. Secondary objectives were to characterize
the pharmacokinetic profiles of BIBF 1120 and pemetrexed and to obtain preliminary
anti-tumour efficacy information.